Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Lung cancer #NCT07563738 #2025-524620-22-00
Partie 2 - Cohorte Sotorasib, CBNPC prétraités
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Orion Pharma
Phase 1 / Phase 2 Lung cancer #NCT07563738 #2025-524620-22-00
Partie 2 - Cohorte Sotorasib, CBNPC naïfs de traitement
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
4 recruiting sites
Orion Pharma
Phase 1 / Phase 2 Lung cancer Stomach and esophageal cancer Head and neck cancer Cervical / Vulvar / Vaginal cancer #NCT06747585 #2024-515459-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Esophagus Cervical cancer
Required histologic sub types
Squamous NSCLC Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2 Lung cancer Stomach and esophageal cancer Head and neck cancer Cervical / Vulvar / Vaginal cancer #NCT06747585 #2024-515459-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Esophagus Cervical cancer
Required histologic sub types
Squamous NSCLC Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2 Lung cancer Stomach and esophageal cancer Head and neck cancer Cervical / Vulvar / Vaginal cancer #NCT06747585 #2024-515459-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Esophagus Cervical cancer
Required histologic sub types
Squamous NSCLC Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2 Prostate cancer #NCT07332455 #2025-523874-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
2 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Breast cancer #NCT07100106 #2025-521128-31-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
4 recruiting sites
Genentech, Inc
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT03526835 #2017-004745-24
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
Other KRAS BRAF HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
7 recruiting sites
Merus
Phase 1 / Phase 2 Kidney cancer #NCT07293351
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
1 recruiting site
Bristol-Myers Squibb
Phase 1 / Phase 2 Kidney cancer #NCT07293351
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
1 recruiting site
Bristol-Myers Squibb